epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab — Competitive Intelligence Brief

epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab (epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anthracycline antibiotic, alkylating agent, taxane, platinum-based alkylati

phase 3 anthracycline antibiotic, alkylating agent, taxane, platinum-based alkylating agent, PD-1 inhibitor DNA, microtubules, PD-1 Oncology Small molecule

Target snapshot

epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab (epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab) — Lund University Hospital. Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis in cancer cells. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division. Carboplatin is a platinum-based alkylating agent that cross-links DNA, causing cell death. Pembrolizumab is a monoclonal antibody that blocks PD-1, enhancing T-cell mediated immune response against cancer cells.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab TARGET	epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab	Lund University Hospital	phase 3	anthracycline antibiotic, alkylating agent, taxane, platinum-based alkylating agent, PD-1 inhibitor	DNA, microtubules, PD-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anthracycline antibiotic, alkylating agent, taxane, platinum-based alkylating agent, PD-1 inhibitor class)

1. Lund University Hospital · 1 drug in this class